(loo-sin-act-ant) ,


(trade name)


Therapeutic: anti rds agents
Pharmacologic: pulmonary surfactants


Prevention of Respiratory Distress Syndrome (RDS) in premature infants who are at high risk. Not indicated for (Adult Respiratory Distress Syndrome) ARDS.


Provides replacement pulmonary surfactant; lowers surface tension which stabilizes alveoli from collapse.

Therapeutic effects

↓ incidence of RDS at 24 hr with decreased associated mortality.


Absorption: Action is local following intratracheal administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (effects on surface tension)

Intratrachealunknownunknown up to 6 hr


Contraindicated in: None noted.
Use Cautiously in: Frequent assessment is necessary; modifications in oxygen/ventilatory support may be required.

Adverse Reactions/Side Effects


  • oxygen desaturation


  • bradycardia


  • pallor


  • reflux into endotracheal tube/endotracheal tube obstruction


Drug-Drug interaction

None noted.


Intratracheal (Neonates) 5.8 mL/kg birth weight may be repeated no more frequently than every 6 hr, not to exceed 4 doses in the first 48 hr of life.


Intratracheal suspension (contains phospholipids): 8.5 mL/vial

Nursing implications

Nursing assessment

  • Monitor respiratory status (lung sounds, oxygen saturation) frequently during therapy.
  • Assess for adverse reactions (bradycardia, oxygen desaturation, reflux of drug into entotracheal tube, airway/endotracheal tube obstruction) frequently during treatment. If these occur, interrupt therapy and assess clinical condition. Suctioning or reintubation may be required. Continue treatment once infant is stable.

Potential Nursing Diagnoses

Ineffective breathing pattern (Indications)
Ineffective airway clearance (Adverse Reactions)


  • Intratracheal: Should be administered by clinicians experienced in intubation, ventilator management, and care of premature infants.
    • Up to 4 doses can be administered within the first 48 hrs of life; give no more frequently than every 6 hrs.
    • Warm vial for 15 min in preheated dry block heater set at 44°. After warming, shake vial vigorously until suspension is uniform and free-flowing. Solution should ve opaque white to off-white. Record date and time warmed in space provided on carton. May be stored for up to 2 hrs after warming at room temperature; do not return to refrigerator. Discard is not used within 2 hrs. Vials are single-use.
    • Slowly draw up appropriate amount of lucinactant using a 16 or 18 gauge needle.
    • Assure patency and proper placement of endotracheal tube; may be suctioned before administration. Allow infant to stabilize before administering. Position infant in right lateral decubitus position with head and thorax inclined upward 30°. Attach syringe containing lucinactant to a 5–French end-hole catheter. Thread catheter through a Bodai valve or equivalent device that allows maintenance of positive end-expiratory pressure, then advance tip of catheter into endotracheal tube. Position catheter such that tip is slightly distal to end of endotracheal tube.
    • Each dose is delivered in 4 aliquots. Instill first aliquot (1/4 of total volume) as a bolus while continuing positive pressure mechanical ventilation and maintaining positive end-expiratory pressure of 4 or 5 cm H2O. Adjust ventilator settings to maintain appropriate oxygenation and ventilation. Once infant is stable and oxygen saturation is at least 90% and heart rate is >120 beats per min, repeat procedure with infant in left lateral decubitus position. Repeat procedure with infant in right then left decubitus position for 4 aliquots. Evaluate infant's respiratory status between aliquots.
    • After instillation of last aliquot, remove catheter and resume ventilation. Keep infant's head elevated at least 10° for at least 1–2 hr. Do not suction infant during first hr after dosing unless signs of significant airway obstruction occur.

Patient/Family Teaching

  • Explain purpose of therapy to parents.

Evaluation/Desired Outcomes

  • Decrease in signs of RDS.
References in periodicals archive ?
The clinical use of Aerosur[R] which is the aerosol form of Lucinactant (Surfaxin[R]), which was produced byMazela et al.
A new surfactant, lucinactant, as been approved for prevention of respiratory distress syndrome in premature infants, the fifth surfactant approved in the United States, the Food and Drug Administration announced.
The safety and efficacy of lucinactant was demonstrated in a randomized active controlled multidose study of 1,294 premature infants, comparing it with two of the other approved surfactants, according to the FDA statement announcing the approval.
In the study, the infants were treated with lucinactant (Surfaxin), colfosceril palmitate (Exosurf), or beractant (Survanta) within 30 minutes of birth.
The most common side effects associated with the lucinactant were associated with intratracheal administration, and included endotracheal tube reflux, endotracheal tube obstruction, and need for dose interruption, the statement said.
Lucinactant, which is a suspension formulation intended for intratracheal use only, will be marketed as Surfaxin by Discovery Laboratories Inc.
Lucinactant Comparison Trial to Colfosceril palmitate and Beractant
19) Lucinactant is a synthetic surfactant not yet approved by the FDA containing 2 phospholipids and a synthetic peptide that the sponsor claims has an SP-B activity.
The average numbers per hospital in the strata [less than or equal to] 1,000 g birth weight were <6 patients in the lucinactant and colfosceril palmitate groups and <3 patients in the beractant group.
Additionally, the conduct of this trial in so many hospitals and in countries whose neonatal units have little experience in randomized clinical trials, as well as the small fraction of consented patients actually randomized, are issues that cause concern about the reality of the large mortality benefit for lucinactant that would not be predicted from previous basic science or clinical data.
If the commercial promoter of lucinactant considered possible the mortality benefit reported by Moya et al 2005, they would have either initiated a well-designed, actively controlled, randomized clinical trial to confirm this possibility or requested a "Treatment Protocol" from the FDA to make this "life saving" medicine available on humanitarian grounds.
The use of lucinactant is being created as an aerosolized agent.